{"doi":"10.1089/dtom.2025.0018","title":"Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) and GLP-1/Gastrointestinal Peptide RA (GLP-1/GIP-RA) Use in Adolescents and Young Adults with Type 1 Diabetes and Overweight or Obesity","abstract":"Background: Many young people with type 1 diabetes have overweight or obesity (OW/OB). OW/OB increases risks of cardiovascular and kidney disease, leading causes of death in type 1 diabetes. Semaglutide, a glucagon-like peptide receptor agonist (GLP-1-RA), improves body mass index (BMI) and glycemia in adults with type 1 diabetes and OW/OB. However, GLP-1-RA and GLP-1/gastric inhibitory polypeptide (GIP)-RA data are lacking in younger patients with type 1 diabetes. Methods: We assessed real-world use of GLP-1-RA and GLP-1/GIP-RA in 33 youth/young adults with type 1 diabetes and OW/OB. Results: From baseline to 12 months, HbA1c decreased by 0.32% (±0.12), BMI by 2.2 kg/m 2 (± 0.38), weight by 7.0 kg (±1.5), continuous glucose monitoring (CGM) average glucose by 19.2 mg/dL (±6.7) and time above range by 10.8% (±3.8); CGM time in range increased by 11.7%. Insulin dose also decreased by 14.6 units/day (±5.7) at 6 months. Conclusions: These findings suggest GLP-1-RA and GLP-1/GIP-RA are promising options for treating type 1 diabetes complicated by OW/OB in youth and young adults.","journal":"Diabetes Technology and Obesity Medicine","year":2025,"id":532240,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.957,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1413410,"name":"Tyler Dobbs","orcid":"0000-0003-2088-1370","position":1,"is_corresponding":false},{"id":1413821,"name":"Claire Zimmerman","orcid":null,"position":2,"is_corresponding":false},{"id":588949,"name":"Gregory P. Forlenza","orcid":"0000-0003-3607-9788","position":3,"is_corresponding":false},{"id":1045516,"name":"G. Todd Alonso","orcid":"0000-0002-5676-761X","position":4,"is_corresponding":false},{"id":7391,"name":"Kristen J. Nadeau","orcid":"0000-0002-0477-3356","position":5,"is_corresponding":false},{"id":1413820,"name":"Chiara M. Lopach","orcid":null,"position":0,"is_corresponding":true}],"reference_count":13,"raw_metadata":null,"created_at":"2026-07-19T02:51:23.237536Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}